Wakamoto Pharmaceutical (4512) Reports Financial Results: Net Sales Up 11.9% YoY

Wakamoto Pharmaceutical (4512) has announced its financial results, posting net sales of 2.425 billion yen, an increase of 11.9% year-on-year. Meanwhile, profitability faced pressures, with an operating loss of 136 million yen and an ordinary loss of 107 million yen, though the company managed to secure a net profit of 6 million yen.

From a financial structure and valuation perspective, the company maintains a robust equity ratio of 73.9%, indicating a highly stable financial foundation. Retained earnings stand at 4.68 billion yen, alongside 2.01 billion yen in cash and cash equivalents, comfortably covering interest-bearing debt of 400 million yen. Although operating cash flow was -490 million yen and free cash flow registered at -1.14 billion yen, the solid capital base and ample liquidity provide a cushion to support medium- to long-term business operations.